189 related articles for article (PubMed ID: 18928058)
21. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres.
Diwan M; Tafaghodi M; Samuel J
J Control Release; 2002 Dec; 85(1-3):247-62. PubMed ID: 12480329
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-12 induces a Th1-like response to Burkholderia mallei and limited protection in BALB/c mice.
Amemiya K; Meyers JL; Trevino SR; Chanh TC; Norris SL; Waag DM
Vaccine; 2006 Feb; 24(9):1413-20. PubMed ID: 16213631
[TBL] [Abstract][Full Text] [Related]
23. Mucosal and systemic immune responses of mice to tetanus toxoid coadministered nasally with AFCo1.
Romeu B; González E; Del Campo J; Acevedo R; Zayas C; Valdés Y; Cabrera O; Cuello M; Balboa J; Lastre M; Pérez O
Can J Microbiol; 2011 Mar; 57(3):256-61. PubMed ID: 21358768
[TBL] [Abstract][Full Text] [Related]
24. Primary immune response to liposomal tetanus toxoid in mice: the effect of mediators.
Davis D; Gregoriadis G
Immunology; 1989 Oct; 68(2):277-82. PubMed ID: 2509329
[TBL] [Abstract][Full Text] [Related]
25. Marine gastropod hemocyanins as adjuvants of non-conjugated bacterial and viral proteins.
Gesheva V; Idakieva K; Kerekov N; Nikolova K; Mihaylova N; Doumanova L; Tchorbanov A
Fish Shellfish Immunol; 2011 Jan; 30(1):135-42. PubMed ID: 20887791
[TBL] [Abstract][Full Text] [Related]
26. Comparison of adjuvant activities of aluminium phosphate, calcium phosphate and stearyl tyrosine for tetanus toxoid.
Gupta RK; Siber GR
Biologicals; 1994 Mar; 22(1):53-63. PubMed ID: 8068314
[TBL] [Abstract][Full Text] [Related]
27. Strong T cell type-1 immune responses to HIV-1 Tat (1-72) protein-coated nanoparticles.
Cui Z; Patel J; Tuzova M; Ray P; Phillips R; Woodward JG; Nath A; Mumper RJ
Vaccine; 2004 Jun; 22(20):2631-40. PubMed ID: 15193389
[TBL] [Abstract][Full Text] [Related]
28. Liposomes as adjuvants with immunopurified tetanus toxoid: influence of liposomal characteristics.
Davis D; Gregoriadis G
Immunology; 1987 Jun; 61(2):229-34. PubMed ID: 3596639
[TBL] [Abstract][Full Text] [Related]
29. Intranasal immunization with tetanus toxoid and CNF1 as a new mucosal adjuvant protects BALB/c mice against lethal challenge.
Munro P; Flatau G; Lemichez E
Vaccine; 2007 Dec; 25(52):8702-6. PubMed ID: 18035455
[TBL] [Abstract][Full Text] [Related]
30. The context of tetanus toxoid application influences the outcome of antigen-specific and self-directed humoral immune response.
Stojanović M; Zivković I; Inić-Kanada A; Petrusić V; Mićić M; Dimitrijević L
Microbiol Immunol; 2009 Feb; 53(2):89-100. PubMed ID: 19291092
[TBL] [Abstract][Full Text] [Related]
31. Development of novel fusogenic vesosomes for transcutaneous immunization.
Mishra V; Mahor S; Rawat A; Dubey P; Gupta PN; Singh P; Vyas SP
Vaccine; 2006 Jul; 24(27-28):5559-70. PubMed ID: 16730102
[TBL] [Abstract][Full Text] [Related]
32. Immunomodulatory activity of novel adjuvant formulations based on Montanide ISA oil-based adjuvants and peptidoglycan monomer.
Habjanec L; Halassy B; Tomasić J
Int Immunopharmacol; 2008 May; 8(5):717-24. PubMed ID: 18387514
[TBL] [Abstract][Full Text] [Related]
33. Effects of supplementation with tocotrienol-rich fraction on immune response to tetanus toxoid immunization in normal healthy volunteers.
Mahalingam D; Radhakrishnan AK; Amom Z; Ibrahim N; Nesaretnam K
Eur J Clin Nutr; 2011 Jan; 65(1):63-9. PubMed ID: 20859299
[TBL] [Abstract][Full Text] [Related]
34. Vaxfectin, a cationic lipid-based adjuvant for protein-based influenza vaccines.
Hartikka J; Bozoukova V; Yang CK; Ye M; Rusalov D; Shlapobersky M; Vilalta A; Wei Q; Rolland A; Smith LR
Vaccine; 2009 Oct; 27(46):6399-403. PubMed ID: 19552895
[TBL] [Abstract][Full Text] [Related]
35. CpG oligonucleotide, host defense peptide and polyphosphazene act synergistically, inducing long-lasting, balanced immune responses in cattle.
Kovacs-Nolan J; Mapletoft JW; Latimer L; Babiuk LA; Hurk Sv
Vaccine; 2009 Mar; 27(14):2048-54. PubMed ID: 19428829
[TBL] [Abstract][Full Text] [Related]
36. Modulation of the immune response to tetanus toxoid by polylactide-polyglycolide microspheres.
Walker KB; Xing DK; Sesardic D; Corbel MJ
Dev Biol Stand; 1998; 92():259-67. PubMed ID: 9554281
[TBL] [Abstract][Full Text] [Related]
37. Enhancement of vaccine-specific cellular immunity in infants by passively acquired maternal antibody.
Rowe J; Poolman JT; Macaubas C; Sly PD; Loh R; Holt PG
Vaccine; 2004 Sep; 22(29-30):3986-92. PubMed ID: 15364448
[TBL] [Abstract][Full Text] [Related]
38. Single dose vaccine based on biodegradable polyanhydride microspheres can modulate immune response mechanism.
Kipper MJ; Wilson JH; Wannemuehler MJ; Narasimhan B
J Biomed Mater Res A; 2006 Mar; 76(4):798-810. PubMed ID: 16345084
[TBL] [Abstract][Full Text] [Related]
39. Low-frequency ultrasound as a transcutaneous immunization adjuvant.
Tezel A; Paliwal S; Shen Z; Mitragotri S
Vaccine; 2005 May; 23(29):3800-7. PubMed ID: 15893617
[TBL] [Abstract][Full Text] [Related]
40. Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice.
Quintilio W; Kubrusly FS; Iourtov D; Miyaki C; Sakauchi MA; Lúcio F; Dias Sde C; Takata CS; Miyaji EN; Higashi HG; Leite LC; Raw I
Vaccine; 2009 Jun; 27(31):4219-24. PubMed ID: 19393709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
